A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NCT04302025)

🧪 Interventions in This Study

• Alectinib (DRUG)
• Entrectinib (DRUG)
• Vemurafenib (DRUG)
• Cobimetinib (DRUG)
• Pralsetinib (DRUG)
• Atezolizumab (DRUG)
• SBRT (DRUG)
• Chemotherapy (DRUG)
• Divarasib (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. for Neoadjuvant Therapy:
2. Pathologically documented NSCLC:
3. Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) NSCLC staging system
4. T4 primary NSCLC will be allowed only on the basis of size. Invasion of the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodules in a different ipsilateral lobe is not permitted
5. All participants will undergo clinical staging using computed tomography (CT) and positron emission tomography (PET) scanning, as well as brain imaging using magnetic resonance imaging (MRI). Invasive mediastinal staging by either mediastinoscopy or endo-bronchial ultrasonography is highly encouraged for participants with radiographically suspected mediastinal nodal disease (i.e., N2) but not mandated if the CT or PET scans showed no evidence of N2 disease
6. Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories and showing at least one of the following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600 mutation, RET fusion, PD-L1 expression in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)-approved test, KRAS G12C mutation
7. Measurable disease, as defined by RECIST v1.1
8. NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground glass opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured based on the solid component only, exclusive of the ground glass opacity component
9. Evaluated by the attending surgeon prior to study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and verify that the participant is medically operable
10. Adequate pulmonary function to be eligible for surgical resection with curative intent
11. Adequate cardiac function to be eligible for surgical resection with curative intent
12. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

• City of Hope Comprehensive Cancer Center — Duarte, California
• City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
• USC Norris Cancer Center — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• University of California Los Angeles - Jonsson Comprehensive Cancer Center — Los Angeles, California
• The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange — Orange, California
• UC Davis Comprehensive Cancer Center — Sacramento, California
• UCSF Helen Diller Family CCC — San Francisco, California
• University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) — Aurora, Colorado
• Yale Cancer Center — New Haven, Connecticut
• MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) — Washington D.C., District of Columbia
• Moffitt Cancer Center — Tampa, Florida
• Northwestern University — Chicago, Illinois
• Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
• Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
• Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
• Boston Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center — Farmington Hills, Michigan
• Mayo Clinic — Rochester, Minnesota
• Ellis Fischel Cancer Center — Columbia, Missouri
• Siteman Cancer Center - Washington University Medical Campus — St Louis, Missouri
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
• Laura and ISAAC Perlmutter Cancer Center at NYU Langone. — New York, New York

📞 Contact the Study Coordinator

Phone: (888) 662-6728

Email: global-roche-genentech-trials@gene.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Anchorage, Alaska
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer — Los Angeles, California

Explore by condition: All Non-small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.